Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice
- 1 June 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 294 (6), E1109-E1118
- https://doi.org/10.1152/ajpendo.00016.2008
Abstract
Intracellular lipid accumulation (steatosis) and resultant lipotoxicity are key features of diabetic cardiomyopathy. Since cardiac hormone-sensitive lipase (HSL) is activated in diabetic mice, we sought to explore a pathophysiological function of cardiac HSL in the development of diabetic cardiomyopathy. Transgenic (Tg) mice with heart-specific HSL overexpression were generated, and cardiac histology, function, lipid profile, and gene expressions were analyzed after induction of diabetes by streptozotocin. Electron microscopy showed numerous lipid droplets in wild-type (Wt) hearts after 3 wk of diabetes, whereas Tg mice showed no lipid droplet accumulation. Cardiac content of acylglycerides was increased ∼50% with diabetes in Wt mice, whereas this was blunted in Tg hearts. Cardiac lipid peroxide content was twofold lower in Tg hearts than in Wt hearts. The mRNA expressions for peroxisome proliferator-activated receptor-α, genes for triacylglycerol synthesis, and lipoprotein lipase were increased with diabetes in Wt hearts, whereas this induction was absent in Tg hearts. Expression of genes associated with lipoapoptosis was decreased, whereas antioxidant protein metallothioneins were increased in diabetic Tg hearts. Diabetic Wt hearts showed interstitial fibrosis and increased collagen content. However, Tg hearts displayed no overt fibrosis, concomitant with decreased expression of collagens, transforming growth factor-β, and matrix metalloproteinase 2. Notably, mortality during the experimental period was approximately twofold lower in diabetic Tg mice compared with Wt mice. In conclusion, since HSL overexpression inhibits cardiac steatosis and fibrosis by apparently hydrolyzing toxic lipid metabolites, cardiac HSL could be a therapeutic target for regulating diabetic cardiomyopathy.Keywords
This publication has 51 references indexed in Scilit:
- Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in miceJCI Insight, 2007
- Lipids in the heart: a source of fuel and a source of toxinsCurrent Opinion in Lipidology, 2007
- A Critical Role for Peroxisomal Proliferator-Activated Receptor-α Nuclear Receptors in the Development of Cardiomyocyte Degeneration and NecrosisThe American Journal of Pathology, 2006
- Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathyFree Radical Biology & Medicine, 2006
- The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic CardiomyopathyJournal of the American College of Cardiology, 2006
- Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozymeFree Radical Biology & Medicine, 2006
- Downregulation of Peroxisome Proliferator–Activated Receptor-α Gene Expression in a Mouse Model of Ischemic Cardiomyopathy Is Dependent on Reactive Oxygen Species and Prevents LipotoxicityCirculation, 2005
- Expression of human hormone-sensitive lipase in white adipose tissue of transgenic mice increases lipase activity but does not enhance in vitro lipolysisJournal of Lipid Research, 2003
- Hormone-sensitive lipaseJournal of Lipid Research, 2002
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972